Phuturdex › Diseases › Mental disorder
Drugs in development · updated 30 October 2026
Mental disorder: drugs in development
As of 30 October 2026 there are 23 active clinical trials (recruiting or ongoing, phases I–III) on 24 drugs for mental disorder. 12 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MelatoninSlenyto®, Circadin® | II–III | 2 | NCT06062953 |
| Cleminorexton | II–III | 1 | NCT07598708 |
| D-Serine | III | 1 | NCT07263022 |
| Ecopipam | III | 1 | NCT06021522 |
| Fasedienol Nasal Spray | III | 1 | NCT06615557 |
| GNR-055 | II–III | 1 | NCT05208281 |
| ML-007C-MA | II | 3 | NCT07459647 |
| GSK4527226 | II | 1 | NCT07105709 |
| Hydroxynorketamine | II | 1 | NCT06511908 |
| Neflamapimod | II | 1 | NCT07033481 |
| PsilocybinPsilocybine | II | 1 | NCT06341426 |
| LY3954068 | I | 1 | NCT06297590 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DonanemabKisunla® | III | 2 | NCT05508789 |
| DexamethasoneDexametasone, Dextenza | III | 1 | NCT05738486 |
| LumateperoneCaplyta® | III | 1 | NCT06482554 |
| ModafinilProvigil® | III | 1 | NCT07263022 |
| QuetiapineSeroquel Xr® | II–III | 1 | NCT06062953 |
| RisperidoneRisvan®, Uzedy® | III | 1 | NCT06482554 |
| N-AcetylcysteineAcetylcysteine, Acetadote | II | 1 | NCT04381897 |
| RituximabRuxience, Rituxan | II | 1 | NCT04323566 |
| SemaglutideWegovy, Rybelsus | II | 1 | NCT06548490 |
| 18F-AV-1451[18F] Flortaucipir, Flortaucipir F18 | I | 1 | NCT06297590 |
| DexmedetomidineIgalmi®, Precedex® | I | 1 | NCT06702488 |
| KetamineKetalar® | I | 1 | NCT05962424 |
Sorted by most advanced phase and number of active trials.
All 24 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Alzheimer's disease 157 drugs
- Major depressive disorder 72 drugs
- Cognitive dysfunction 94 drugs
- Alcoholism 53 drugs
- Depression 73 drugs
- Post-traumatic stress disorder 39 drugs
- Schizophrenia 76 drugs
- Opioid-related disorders 49 drugs
- Anxiety disorder 32 drugs
- Dementia 54 drugs
- Autism spectrum disorder 35 drugs
- Depressive Disorder, Treatment-Resistant 21 drugs
Broader categories
- Neurologic Manifestations 15 drugs
- Neurobehavioral manifestation 8 drugs
- Schizophrenia spectrum disorder 3 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Nervous System Diseases 39 drugs
- Nutritional and metabolic diseases 5 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001523 “Mental Disorders”.